既往登革病毒暴露与增强的寨卡病毒特异性ADCC活性相关:一项纵向人类队列研究
研究基于2016—2018年美国两中心46例PCR确诊寨卡病毒(ZIKV)感染者的纵向血清样本,按基线登革病毒(DENV)中和抗体分为DENV暴露组(n=13)与未暴露组(n=33)。用自然杀伤细胞毒试验检测ZIKV特异性ADCC,发现既往DENV暴露者ADCC峰值与早期、晚期累积ADCC均更高,而ZIKV中和效率两组无差异。
要点
- 既往DENV暴露者ZIKV特异性ADCC峰值GMT为15,104,显著高于未暴露者的1,819。
- 两组ZIKV中和效率在ADCC峰值时无差异,提示既往DENV暴露影响Fc介导免疫而非中和。
- ZIKV ADCC/IgG归一化后DENV暴露组仍更高(GMT 2,230 vs 735.6,P=0.0107)。
核心结论
- 既往DENV感染与更高水平的ZIKV特异性ADCC相关,尽管ZIKV中和作用相似,提示既往DENV暴露塑造了中和之外的Fc介导黄病毒免疫。
研究设计与样本
- 前瞻性队列的纵向血清分析,纳入2016—2018年美国两中心46例PCR确诊ZIKV病例,随访6—409天。
- 按基线DENV中和抗体分为DENV暴露组(n=13)与DENV未暴露组(n=33),用自然杀伤细胞毒试验检测ZIKV特异性ADCC。
主要发现
- DENV暴露组ZIKV特异性ADCC峰值GMT为15,104,未暴露组为1,819(P<0.0001)。
- 早期(≤80天)累积ADCC的AUC为918,540 vs 42,752(P=0.0012),晚期(>80天)为953,694 vs 182,004(P=0.0037)。
- ADCC峰值幅度与DENV或ZIKV中和抗体峰值无相关性,ADCC峰值时ZIKV中和效率两组无差异。
- ZIKV ADCC归一化至ZIKV IgG后,DENV暴露组GMT为2,230,未暴露组为735.6(P=0.0107)。
临床怎么用
- 对既往DENV流行区人群评估ZIKV免疫时应关注ADCC等Fc介导功能,而不仅看中和抗体。
- ADCC的临床意义尚待研究,暂不宜直接用于临床决策或保护性评估。
局限性
- 样本量较小(46例,DENV暴露组仅13例),随访时间跨度不一(6—409天)。
- ADCC为体外自然杀伤细胞毒试验指标,其免疫病理或保护意义尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prior dengue virus (DENV) infection is common in regions affected by Zika virus (ZIKV) and may shape immune responses to subsequent ZIKV infection. Although cross-reactive neutralizing and disease-enhancing antibodies have been extensively studied, the effect of prior DENV immunity on antibody-dependent cellular cytotoxicity (ADCC) responses to ZIKV remains unclear. METHODS: Longitudinal serum samples were obtained and analyzed from a prospective cohort of 46 PCR-confirmed ZIKV cases enrolled at two U.S. sites between 2016-2018 (follow-up visits 6-409 days). ZIKV cases were classified as DENV-experienced (n=13) or DENV-naïve groups (n=33) based on detection of DENV neutralizing antibodies at baseline. ZIKV-specific ADCC activity was measured using a natural killer cell cytotoxicity assay. RESULTS: DENV-experienced individuals had significantly higher peak ZIKV-specific ADCC responses (geometric mean titers [GMT] 15,104 vs 1,819; P<0.0001) and greater cumulative ADCC responses during early (≤80 days, AUC 918,540 vs 42,752; P = 0.0012) and late convalescent phases (>80 days, AUC 953,694 vs 182,004; P=0.0037). Peak ZIKV ADCC magnitude did not correlate with peak DENV or ZIKV antibody neutralizing titers, and ZIKV neutralization efficiency at the time of peak ZIKV ADCC did not differ between groups. However, ZIKV ADCC normalized to ZIKV IgG was significantly higher among DENV-experienced individuals (GMT 2,230 vs 735.6; P=0.0107). CONCLUSIONS: Prior DENV infection was associated with greater ZIKV-specific ADCC magnitude, despite similar ZIKV neutralization, suggesting that prior DENV exposure shapes Fc-mediated flavivirus immunity beyond neutralization. Future studies are needed to assess the clinical implications of these antibodies in immunopathology and protection.
引用
- McCaffery JN, Chen X, Gibson T, et al. Prior Dengue Virus Exposure is Associated with Enhanced Zika Virus-Specific ADCC Activity in a Longitudinal Human Cohort. J Infect Dis. 2026. PMID: 42615534. doi:10.1093/infdis/jiag429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。